Structure via PubChem · Public domain (PubChem)
elvucitabine
Sign in to saveAlso known as B-L-Fd4C
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection.
Chemical data
- Formula
- C9H10FN3O3
- Molecular weight
- 227.19 g/mol
- IUPAC name
- 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
- SMILES
- C1=C[C@H](O[C@H]1CO)N2C=C(C(=NC2=O)N)F
- InChIKey
- HSBKFSPNDWWPSL-VDTYLAMSSA-N
- XLogP
- -1.3
- Polar surface area
- 88.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- HIV infection, chronic hepatitis B virus infection
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 227.071
Show 5 more facts
- Commons category
- Elvucitabine
- stereoisomer of
- dexelvucitabine
- chemical formula
- C₉H₁₀FN₃O₃
- canonical SMILES
- C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F
- isomeric SMILES
- C1=C[C@H](O[C@H]1CO)N2C=C(C(=NC2=O)N)F
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection.
Elvucitabine belongs to a class of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs). By blocking reverse transcriptase enzymes, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.
Excerpted from Wikipedia’s “elvucitabine” article, available under the CC BY-SA 4.0 licence.